Ketamine Therapy in Missouri: A 2026 Guide

For Missourians living with treatment-resistant depression or related mood disorders, ketamine therapy has become a meaningful option worth understanding. Clinics offering IV ketamine infusions and the FDA-approved nasal spray Spravato (esketamine) can be found in Kansas City, St. Louis, Springfield, and a growing number of other Missouri communities. This guide covers the clinical basics, Missouri’s regulatory framework, insurance landscape, and what to look for in a provider.

What Ketamine Therapy Is — and Is Not

Ketamine was first developed as a surgical anesthetic and remains widely used in that role. At carefully controlled, sub-anesthetic doses, it has demonstrated the ability to rapidly reduce depressive symptoms in some patients — a finding that has generated significant clinical interest because most standard antidepressants require weeks to take effect.

The FDA approved Spravato (esketamine) in 2019 for treatment-resistant depression (ICD-10: F33.2) — broadly defined as failing to respond adequately to at least two antidepressant trials of sufficient dose and duration. It was subsequently approved for major depressive disorder with acute suicidal ideation (ICD-10: F32.9). IV ketamine infusions for psychiatric purposes remain off-label; when billed, they use CPT codes such as 99213/99214 for evaluation and management, 90791 for psychiatric evaluation, and J3490 for off-label drug administration.

Ketamine therapy is not a cure and is not appropriate for everyone. Patients with uncontrolled hypertension, active psychosis, certain cardiovascular conditions, or a history of ketamine misuse are generally not candidates. A thorough pre-treatment evaluation by a licensed clinician is essential.

Missouri Licensing and Oversight

In Missouri, ketamine can only be prescribed and administered by or under the direct supervision of a physician licensed by the Missouri Board of Registration for the Healing Arts, the state agency responsible for licensing MDs and DOs. This board operates under the Missouri Division of Professional Registration within the Department of Commerce and Insurance.

Advanced practice registered nurses (APRNs) in Missouri have faced historically restrictive collaborative practice requirements, though the landscape has evolved. As of recent legislative sessions, Missouri has made incremental progress on APRN practice authority, but most APRNs still require a collaborative practice arrangement with a physician for prescribing Schedule III controlled substances, which includes ketamine.

For Spravato, the FDA’s REMS (Risk Evaluation and Mitigation Strategy) program applies uniformly across all states. Every Spravato dispensing site must be REMS-certified, and every dose must be administered in a healthcare setting with a mandatory two-hour post-dose observation period. Home administration is not permitted under any circumstances.

You can verify a Missouri physician’s license status and check for any disciplinary actions through the Missouri Division of Professional Registration’s online lookup. The NPPES NPI Registry provides additional credential verification by specialty and practice location.

Insurance Coverage in Missouri

MO HealthNet (Missouri Medicaid): Missouri’s Medicaid program, MO HealthNet, covers Spravato for eligible enrollees who meet clinical criteria. Missouri expanded Medicaid under the Affordable Care Act in 2021, making a larger portion of the low-income population eligible for MO HealthNet. Coverage for Spravato requires prior authorization and documentation of treatment-resistant depression meeting clinical thresholds. Missouri’s fee-for-service and managed care Medicaid populations have different billing pathways, so patients should confirm with their specific MO HealthNet plan.

Anthem Blue Cross Blue Shield of Missouri is one of the largest commercial insurers operating in the state, active in both employer-sponsored and individual marketplace plans. Anthem Missouri has a medical policy for Spravato that requires prior authorization and documentation of failed prior antidepressant trials. Members should confirm their specific plan’s requirements — coverage terms for HMO, PPO, and marketplace plans can differ.

Other significant commercial payers in Missouri include:

UnitedHealthcare of Missouri — covers Spravato subject to prior authorization and step therapy documentation
Cigna Missouri — follows Cigna’s national medical policy with state-specific prior auth requirements
Cox Health Plans — a regional insurer based in Springfield; members should confirm Spravato coverage directly
Burns & McDonnell-sponsored plans and other large Missouri employer plans — coverage varies by employer contract

IV ketamine infusions remain off-label and are not routinely covered by any insurer in Missouri. Most patients pay out of pocket for IV ketamine, and prices vary by clinic.

Missouri’s Mental Health Context

Missouri faces mental health access challenges common to many Midwestern states, including provider shortages in rural areas. Large swaths of Missouri — particularly in the Ozarks, the Bootheel, and northwest Missouri — are designated as Mental Health Professional Shortage Areas (MHPSAs) by the federal government. Ketamine therapy, which requires in-person clinic visits for the treatment itself, may be less accessible to rural Missourians than to residents of Kansas City or St. Louis.

In response, some Missouri providers have adopted hybrid models: telehealth for evaluation, intake, and follow-up, combined with periodic in-person visits to the nearest clinic for infusions or Spravato sessions. This approach can reduce the burden for patients who must travel significant distances.

Missouri has maintained a relatively functional telehealth framework for mental health care following the COVID-19 era expansions. Telehealth psychiatric evaluation, medication management, and therapy are available and covered by both MO HealthNet and most commercial insurers in the state. The key limitation is that the ketamine administration itself — whether IV infusion or Spravato — cannot be conducted via telehealth.

What Patients in Missouri Should Expect

A typical initial IV ketamine series in Missouri consists of six infusions over two to three weeks. Each infusion lasts approximately 40 to 60 minutes, and patients require a driver for the remainder of the day due to the dissociative effects. These effects — which can include altered perception, a dreamlike state, and mild visual or auditory changes — are temporary and generally resolve within an hour of the infusion ending.

For Spravato, the FDA’s approved schedule begins with twice-weekly sessions for the first four weeks, followed by weekly sessions for weeks five through eight, and weekly or biweekly maintenance thereafter. Each session requires in-person supervised self-administration plus the two-hour observation window — plan for a three-hour block per session.

Most Missouri clinics recommend pairing ketamine with ongoing psychotherapy. Evidence supports the view that ketamine’s effects are more durable when paired with therapeutic work. If your clinic does not offer integration therapy directly, ask for a referral to a Missouri-licensed therapist familiar with ketamine care.

Connect with Missouri ketamine providers through our directory.

This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.

Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.